- Home
- RLAY vs LENZ Comparison
RLAY vs LENZ Comparison
Compare RLAY & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | LENZ |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 852.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLAY | LENZ |
|---|---|---|
| Price | $7.82 | $30.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $16.00 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,355,000.00 | ★ $17,500,000.00 |
| Revenue This Year | $27.30 | N/A |
| Revenue Next Year | $7.43 | $285.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | $16.54 |
| 52 Week High | $8.36 | $50.40 |
Technical Indicators
Market Signals| Indicator | RLAY | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 51.27 |
| Support Level | $6.28 | $27.44 |
| Resistance Level | $8.36 | $32.13 |
| Average True Range (ATR) | 0.50 | 2.19 |
| MACD | 0.14 | 1.07 |
| Stochastic Oscillator | 76.56 | 80.93 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.